The investigation of effect of Hab-o Shefa in control of withdrawal symptoms in opioid addicts.

The investigation of effect of Hab-o-Shefa in control of withdrawal symptoms in treatment of opioid addiction to acute detoxification.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201109107518N1

Enrollment

Registered

2012-03-16

Start date

2011-09-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Opioid addiction. Mental and behavioural disorders due to use of opioids

Interventions

Intervention 1: Clonidine is a specific a2-adrenergic receptor agonist that has been widely used in opioid detoxification. Treatment program in this study included the first day 0/2 mg and 2th days 0/

Treatment - Drugs

Clonidine is a specific a2-adrenergic receptor agonist that has been widely used in opioid detoxification. Treatment program in this study included the first day 0/2 mg and 2th days 0/4 mg and 3th day

Hab-o Shefa is a combination drug of Traditional Iranian Medicine that it is combination of different ratios of datura stramonium, Rheum Palmatum, Zingiber Officionalis and Acacia Arabica. This is a c

In this study sugar is used as a placebo.

Eligibility

Sex/Gender

Male

Age

25 Years to 40 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Opioids addiction according to DSM IV; Age between 25 to 40 years old; male; Posittive urinary morphine test? Exclusion criteria: Addiction to stimulants or alchole; Acute incontrollable to physical disease; antisocial or borderline personality or inability to answer questionnaire; Not patient consent for the study; Severe withdrawal symptoms or complications and drug allergies; Beginning of the study positive urinary stimulants test or negative urinary morphine test

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Clinical withdrawal symptoms. Timepoint: Daily. Method of measurement: questionair according to DSM IV.;Objective withdrawal symptoms. Timepoint: Daily. Method of measurement: questionair according to DSM IV.;Subjective withdrawal symptoms. Timepoint: Daily. Method of measurement: questionair according DSM IV.;Depression Bek. Timepoint: Daily. Method of measurement: Bek questionaire.;Depression Hamilton. Timepoint: Daily. Method of measurement: Hamilton questionair.;Craving on opioids. Timepoint: Daily. Method of measurement: Halikas questionaire.	—

Measure

Time frame

Clinical withdrawal symptoms. Timepoint: Daily. Method of measurement: questionair according to DSM IV.;Objective withdrawal symptoms. Timepoint: Daily. Method of measurement: questionair according to DSM IV.;Subjective withdrawal symptoms. Timepoint: Daily. Method of measurement: questionair according DSM IV.;Depression Bek. Timepoint: Daily. Method of measurement: Bek questionaire.;Depression Hamilton. Timepoint: Daily. Method of measurement: Hamilton questionair.;Craving on opioids. Timepoint: Daily. Method of measurement: Halikas questionaire.

—

Secondary

Measure	Time frame
Adverse effect of Hab-o-Shefa and Clonidine. Timepoint: Daily. Method of measurement: Accordingto Traditional Iranian Medicine refrences and textbook of Katzong: tachicardic arrythmia, Blurred vision, Changes in vision- photophobia, constipation, urinary disorder, vertigo, Sleep disorders, Dry mouth, nausea and vomitting, flashing.	—

Countries

Iran (Islamic Republic of)

Contacts

Public Contactseyed mohammad nazari

Medicine callege of Shahed University

drnazari43@gmail.com shamidrezanazari@yahoo.com timshahed@yahoo.com+98 912 808 7714

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026